Article Sidebar
Published:
Jan 11, 2024Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Efficacy of recombinant human brain natriuretic peptide as an adjuvant therapy for severe heart failure, and its impact on oxidative stress and quality of life in patients
Abstract
Methods: The study was conducted on 100 patients with severe heart failure who met the screening criteria for this study. They were evenly but randomly divided into two groups. Patients in the control group were given routine treatment (diuretics and cardiac stimulants) for severe heart failure, while the study group received recombinant human brain natriuretic peptide adjuvant therapy in addition to the treatment administered to the control group. Cardiac function, heart rate, oxidative stress indicators, quality of life levels, and adverse drug reactions during treatment were compared before and after treatment.
Results: After the intervention, the NT-proBNP level in the study group was significantly lower than in the control group while LVEF level was significantly higher than in the control group (p < 0.05). Compared with the control group, the study group showed a significant decrease in heart rate (p < 0.05). The MDA level of the study group was significantly lower than that of the control group while the SOD and GSH-PX levels were significantly higher than those of the control group (p < 0.05). In addition, the GQOLI-74 score of the study group was significantly higher than that of the control group (p < 0.05). Furthermore, there was no statistically significant difference in incidence of adverse reaction between control and study groups (14.0 and 16.0 %, respectively, p < 0.05).
Conclusion: Recombinant human brain natriuretic peptide has a significant therapeutic effect on severe heart failure, thus improving patients' cardiac function, alleviating their oxidative stress state and enhancing their quality of life, and is also safe.
